Kalbe
IDX:KLBFJakarta, Indonesia· Est.
Indonesia's top integrated healthcare group driving growth through innovative biologics and broad consumer health portfolio.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Indonesia's top integrated healthcare group driving growth through innovative biologics and broad consumer health portfolio.
OncologyImmunologyCardiovascularMetabolismInfectious Diseases
Technology Platform
Hybrid platform combining small‑molecule synthesis with biologics manufacturing (monoclonal antibodies, recombinant proteins) and digital health analytics.
Opportunities
Expansion of biosimilar portfolio across ASEAN and leveraging digital health platforms for patient adherence provide growth.
Risk Factors
Regulatory delays for biologics, intense competition from multinational pharma, and currency volatility in emerging markets.
Competitive Landscape
Competes with regional players like Kimia Farma and global giants such as Roche; differentiation stems from its integrated supply chain and emerging biologics capabilities.